Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 4 | 5 |
| 1.1 List of Tables | 6 | 1 |
| 1.2 List of Figures | 7 | 2 |
| 2 Global Hepatitis Therapeutics Market: Introduction | 9 | 2 |
| 2.1 GBI Research Report Guidance | 10 | 1 |
| 3 Global Hepatitis Therapeutics Market: Market Overview | 11 | 11 |
| 3.1 Introduction | 11 | 1 |
| Revenue Forecasts for the Global Hepatitis Therapeutics Market | 12 | 1 |
| 3.2.1 Sales Value | 12 | 1 |
| Annual Cost of Therapy | 13 | 1 |
| 3.2.2 Treatment Usage Patterns | 14 | 1 |
| 3.2.2.1 Diseased Population | 15 | 2 |
| Treatment Seeking Population | 17 | 1 |
| 3.2.2.2 Diagnosed Population | 18 | 1 |
| 3.2.2.3 Prescription Population | 19 | 1 |
| 3.3 Hepatitis Market Drivers | 19 | 1 |
| 3.3.1 Hepatitis C is a Growing Market with Strong Competition and a Promising Pipeline | 19 | 1 |
| 3.3.2 Promising Developments in Hepatitis C Pipeline | 19 | 1 |
| 3.3.3 Steady Increase in Prescription Population | 20 | 1 |
| 3.4 Hepatitis Market Restraints | 20 | 1 |
| 3.4.1 Hepatitis is Rarely Recognized During the Early Stages of the Disease Due to Lack of Symptoms during Acute Phase | 20 | 1 |
| 3.4.2 Low Treatment Seeking Population | 20 | 1 |
| 3.4.3 Loss of Exclusivity Protection in Hepatitis B Market | 20 | 1 |
| 3.5 Generic Share in the Global Hepatitis Market | 21 | 1 |
| 4 Global Hepatitis Market: Therapeutic Landscape | 22 | 23 |
| 4.1 Introduction | 22 | 1 |
| 4.1.1 Hepatitis A | 22 | 1 |
| 4.1.2 Hepatitis B | 22 | 1 |
| 4.2 Overview of Hepatitis A and B Vaccines Market | 23 | 1 |
| 4.2.1 Sales Value | 23 | 1 |
| 4.3 Hepatitis B Market | 24 | 1 |
| 4.3.1 Introduction | 24 | 1 |
| 4.3.2 Sales Value | 25 | 1 |
| 4.3.3 Annual Cost of Therapy | 26 | 1 |
| 4.3.4 Treatment Usage Patterns | 27 | 1 |
| 4.3.4.1 Diseased Population | 28 | 1 |
| 4.3.4.2 Treatment Seeking Population | 29 | 1 |
| 4.3.4.3 Diagnosed Population | 30 | 1 |
| 4.3.4.4 Prescription Population | 31 | 1 |
| 4.3.5 Geographical Segmentation | 32 | 2 |
| 4.4 Hepatitis C Market | 34 | 1 |
| 4.4.1 Introduction | 34 | 1 |
| 4.4.2 Sales Value | 35 | 1 |
| Annual Cost of Therapy | 36 | 1 |
| 4.4.4 Treatment Usage Patterns | 37 | 1 |
| 4.4.4.1 Diseased Population | 38 | 1 |
| 4.4.4.2 Treatment Seeking Population | 39 | 1 |
| 4.4.4.3 Diagnosed Population | 40 | 1 |
| 4.4.4.4 Prescription Population | 41 | 1 |
| 4.4.5 Geographical Segmentation | 42 | 3 |
| 5 Global Hepatitis Market: Geographical Landscape | 45 | 24 |
| 5.1 Geographical Break-up | 45 | 3 |
| 5.2 The US | 48 | 1 |
| 5.2.1 Sales Value | 48 | 1 |
| 5.2.2 Annual Cost of Therapy | 49 | 1 |
| 5.2.3 Treatment Usage Patterns | 50 | 1 |
| 5.2.3.1 Diseased Population | 51 | 1 |
| 5.2.3.2 Treatment Seeking Population | 52 | 1 |
| 5.2.3.3 Diagnosed Population | 53 | 1 |
| 5.2.3.4 Prescription Population | 54 | 1 |
| 5.3 Top Five Countries in Europe | 55 | 1 |
| 5.3.1 Sales Value | 55 | 1 |
| 5.3.2 Annual Cost of Therapy | 56 | 1 |
| 5.3.3 Treatment Usage Patterns | 57 | 1 |
| 5.3.3.1 Diseased Population | 58 | 1 |
| 5.3.3.2 Treatment Seeking Population | 59 | 1 |
| 5.3.3.3 Diagnosed Population | 60 | 1 |
| 5.3.3.4 Prescription Population | 61 | 1 |
| 5.4 Japan | 62 | 1 |
| 5.4.1 Sales Value | 62 | 1 |
| 5.4.2 Annual Cost of Therapy | 63 | 1 |
| 5.4.3 Treatment Usage Patterns | 64 | 1 |
| 5.4.3.1 Diseased Population | 65 | 1 |
| 5.4.3.2 Treatment Seeking Population | 66 | 1 |
| 5.4.3.3 Diagnosed Population | 67 | 1 |
| 5.4.3.4 Prescription Population | 68 | 1 |
| 6 Global Hepatitis Vaccines and Therapeutics Market: Pipeline Analysis | 69 | 12 |
| 6.1 Introduction | 69 | 2 |
| 6.1.1 Research and Development Pipeline Hepatitis B Therapeutics | 71 | 1 |
| 6.1.2 Research and Development Pipeline Hepatitis C Therapeutics | 72 | 1 |
| 6.2 Profiles of Key Late-Stage Vaccines in the Hepatitis A &B Market | 73 | 1 |
| 6.2.1 Heplisav | 73 | 1 |
| 6.2.1.1 Introduction | 73 | 1 |
| 6.2.1.2 Mechanism of Action | 73 | 1 |
| 6.2.1.3 Clinical Trial Management | 73 | 1 |
| 6.3 Molecule Profile for Promising Therapeutics for Hepatitis B under Clinical Development | 74 | 1 |
| 6.3.1 Entecavir + Adefovir combination therapy | 74 | 1 |
| 6.3.1.1 Introduction | 74 | 1 |
| 6.3.1.2 Mechanism of Action | 74 | 1 |
| 6.3.1.3 Clinical Trial Management | 74 | 1 |
| 6.3.2 Truvada (Tenofovir plus Emtricitabine combination therapy) | 74 | 1 |
| 6.3.2.1 Introduction | 74 | 1 |
| 6.3.2.2 Mechanism of Action | 74 | 1 |
| 6.3.2.3 Clinical Trial Management | 75 | 1 |
| 6.4 Molecule Profile for Promising Therapeutics for Hepatitis C under Clinical Development | 75 | 1 |
| 6.4.1 Boceprevir (SCH 503034, narlaprevir) | 75 | 1 |
| 6.4.1.1 Introduction | 75 | 1 |
| 6.4.1.2 Mechanism of Action | 75 | 1 |
| 6.4.1.3 Clinical Trial Management | 75 | 1 |
| 6.4.2 Tenofovir + Emtricitabine Combination therapy | 76 | 1 |
| 6.4.2.1 Introduction | 76 | 1 |
| 6.4.2.2 Clinical Trial Management | 76 | 1 |
| 6.4.3 Zalbin (albinterferon alfa-2b, Joulferon) | 76 | 1 |
| 6.4.3.1 Introduction | 76 | 1 |
| 6.4.3.2 Mechanism of Action | 76 | 1 |
| 6.4.3.3 Clinical Trial Management | 77 | 1 |
| 6.4.4 Telaprevir (VX 905) | 77 | 1 |
| 6.4.4.1 Introduction | 77 | 1 |
| 6.4.4.2 Mechanism of Action | 77 | 1 |
| 6.4.4.3 Clinical Trial Management | 78 | 1 |
| 6.4.5 RG 7128 | 79 | 1 |
| 6.4.5.1 Introduction | 79 | 1 |
| 6.4.5.2 Mechanism of Action | 79 | 1 |
| 6.4.5.3 Clinical Trial Management | 79 | 2 |
| Global Hepatitis Vaccines &Therapeutics Market: Competitive Landscape | 81 | 8 |
| 7.1 Market Share Analysis: Hepatitis | 81 | 1 |
| 7.2 Competitive Profiling | 82 | 1 |
| 7.2.1 Merck &Co., Inc. | 82 | 1 |
| 7.2.1.1 SWOT Analysis | 83 | 1 |
| 7.2.1.2 Product Portfolio | 84 | 1 |
| 7.2.2 F. Hoffmann-La Roche Ltd. | 85 | 1 |
| 7.2.2.1 SWOT Analysis | 85 | 1 |
| 7.2.2.2 Product Portfolio | 86 | 1 |
| 7.2.3 GlaxoSmithKline plc | 87 | 1 |
| 7.2.3.1 SWOT Analysis | 87 | 1 |
| 7.2.3.2 Product Portfolio | 88 | 1 |
| 8 Global Hepatitis Market: Strategic Consolidations | 89 | 7 |
| 8.1 Mergers and Acquisitions | 89 | 1 |
| 8.1.1 Overview | 89 | 1 |
| 8.1.1.1 Deals by Geography | 89 | 1 |
| 8.1.1.2 Deals by Type | 90 | 1 |
| 8.1.2 Summary of M&A Deals (2009-2010) | 90 | 1 |
| 8.1.2.1 China Life Insurance to Acquire Sino Biopharmaceutical | 90 | 1 |
| 8.1.2.2 Diasorin to Acquire MUREX Product Line From Abbott Laboratories | 90 | 1 |
| 8.1.2.3 Nova Laboratories Acquires Cambridge Biostability | 90 | 1 |
| 8.1.2.4 LTT Bio-Pharma Completes the Sale of 19.2% Stake in the Company | 90 | 1 |
| 8.1.2.5 Calzada Acquires Minority Stake in Avexa | 91 | 1 |
| 8.2 R&D Licensing Agreements | 91 | 1 |
| 8.2.1 Summary of Licensing Deals (2009-2010) | 91 | 1 |
| 8.2.1.1 Medivir Enters Into Licensing Agreement With Daewoong Pharmaceutical | 91 | 1 |
| 8.2.1.2 Debiopharm Enters Into Licensing Agreement With Novartis | 91 | 1 |
| 8.2.1.3 Achillion Pharmaceuticals Enters Into Licensing Agreement With GCA Therapeutics | 92 | 1 |
| 8.2.1.4 Advanced Biological Laboratories Enters Into Licensing Agreement With CRP-Sante | 92 | 1 |
| 8.2.1.5 Bristol-Myers Squibb Enters Into An Agreement With ZymoGenetics | 92 | 1 |
| 8.2.1.6 Cyplasin Biomedical Enters Into Licensing Agreement With Virionics | 92 | 1 |
| 8.2.1.7 GlaxoSmithKline Enters Into Licensing Agreement With Gilead Sciences | 93 | 1 |
| 8.2.1.8 Stanford University Enters Into Worldwide Licensing Agreement With Eiger BioPharmaceuticals | 93 | 1 |
| 8.2.1.9 Vertex Pharmaceuticals Amends Agreement With Mitsubishi Tanabe Pharma | 93 | 1 |
| 8.2.1.10 Valeant Pharmaceuticals Enters Into Option Licening Agreement With Schering-Plough | 93 | 1 |
| 8.2.1.11 ViroStatics Enters Into Licensing Agreement With University of Siena | 93 | 1 |
| 8.2.1.12 Chugai Pharmaceutical Signs Licensing Agreement With Romark Laboratories | 94 | 1 |
| 8.2.1.13 Virco Enters Into Licensing Agreement With Siemens Healthcare Diagnostics | 94 | 1 |
| 8.2.1.14 Evivar Medical Enters Into Licensing Agreement With Advanced Biological Laboratories | 94 | 1 |
| 8.2.1.15 Biotecnol And Digna Biotech Enters Into Licensing Agreement With Genentech | 94 | 1 |
| 8.2.1.16 Hadasit Enters Into Licensing Agreement With Immuron | 95 | 1 |
| 9 Global Hepatitis Market: Appendix | 96 | 6 |
| 9.1 Market Definitions | 96 | 1 |
| 9.2 Abbreviations | 96 | 1 |
| 9.3 Research Methodology | 97 | 1 |
| 9.4 Research Methodology | 97 | 4 |
| 9.4.1 Coverage | 97 | 1 |
| 9.4.2 Secondary Research | 97 | 1 |
| 9.4.3 Primary Research | 98 | 1 |
| 9.4.4 Forecasts | 98 | 1 |
| 9.4.4.1 Epidemiology-based Forecasting | 98 | 2 |
| 9.4.5 Expert Panel Validation | 100 | 1 |
| 9.5 Contact Us | 101 | 1 |
| 9.6 Disclaimer | 101 | 1 |